UTHR EBITDA | United Therapeutics Corporation

United Therapeutics Corporation (UTHR) EBITDA

2026-06-30: Basis Reported; EBITDA $355.00M*; Operating income $330.80M; Depreciation and amortization $24.20M*.
2026-03-31: Basis Reported; EBITDA $348.4M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $379.5M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $410.40M*; Operating income $388.50M; Depreciation and amortization $21.90M*.

Complete source-backed ebitda history.

Available history: 2008-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$355.00M*	$330.80M	$24.20M*	$783.30M	45.32%*	$108.00M*	$313.60M*	$99.50M	$146.30M	$206.70M	$39.70M
2026-03-31	Reported	$348.4M	(m)	(m)	(m)	44.58%	$100.80M	$463.30M	$133.40M	$138.20M	$184.10M	$43.40M
2025-12-31	Reported	$379.5M	(m)	(m)	(m)	48.03%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$410.40M*	$388.50M	$21.90M*	$799.50M	51.33%*	$210.50M*	$562.10M*	$100.90M	$127.50M	$182.60M	$99.30M
2025-06-30	Reported	$385.60M*	$364.50M	$21.10M*	$798.60M	48.28%*	$62.20M*	$191.70M*	$87.60M	$134.00M	$212.50M	$98.90M
2025-03-31	Reported	$402.6M	(m)	(m)	(m)	50.68%	$74.90M	$461.20M	$92.50M	$149.00M	$170.10M	$101.30M
2024-12-31	Reported	$377.4M	(m)	(m)	(m)	51.28%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$362.20M*	$343.10M	$19.10M*	$748.90M	48.36%*	$76.50M*	$377.20M*	$83.10M	$103.50M	$219.20M	$79.50M
2024-06-30	Reported	$338.60M*	$319.90M	$18.70M*	$714.90M	47.36%*	$45.10M*	$232.20M*	$77.80M	$139.60M	$177.60M	$77.20M
2024-03-31	Reported	$371.3M	(m)	(m)	(m)	54.79%	$38.20M	$376.50M	$72.90M	$104.10M	$144.40M	$92.00M
2023-12-31	Reported	$273.8M	(m)	(m)	(m)	44.54%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	$340.30M*	$327.00M	$13.30M*	$609.40M	55.84%*	$65.70M*	$346.20M*	$70.10M	$84.70M	$127.60M	$84.20M
2023-06-30	Reported	$326.30M*	$313.40M	$12.90M*	$596.50M	54.70%*	$44.70M*	$106.30M*	$64.10M	$89.00M	$130.00M	$76.00M
2023-03-31	Reported	$297.7M	(m)	(m)	(m)	58.73%	$41.30M	$374.80M	$52.30M	$82.90M	$87.30M	$51.00M
2022-12-31	Reported	$188.8M	(m)	(m)	(m)	38.41%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	$327.20M*	$314.30M	$12.90M*	$516.00M	63.41%*	$68.80M*	$258.60M*	$37.20M	$66.10M	$98.40M	$73.20M
2022-06-30	Reported	$214.50M*	$201.80M	$12.70M*	$466.90M	45.94%*	$17.00M*	$127.00M*	$29.70M	$93.90M	$141.50M	$34.60M
2022-03-31	Reported	$300.5M	(m)	(m)	(m)	65.06%	$13.50M	$288.70M	$25.90M	$69.00M	$79.00M	$68.80M
2021-12-31	Reported	$182.4M	(m)	(m)	(m)	43.93%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	$241.10M*	$228.70M	$12.40M*	$444.70M	54.22%*	$23.30M*	$185.60M*	$27.70M	$79.20M	$109.10M	$41.70M
2021-06-30	Reported	$234.60M*	$222.20M	$12.40M*	$446.50M	52.54%*	$16.30M*	$148.20M*	$37.20M	$74.30M	$112.80M	$43.90M
2021-03-31	Reported	-$52.3M	(m)	(m)	(m)	-13.80%	$10.60M	$89.80M	$23.00M	$303.70M	(m)	$4.20M
2020-12-31	Reported	$78.4M	(m)	(m)	(m)	20.37%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	$232.90M*	$221.10M	$11.80M*	$380.10M	61.27%*	$15.80M*	$250.90M*	$24.00M	$68.70M	(m)	$47.80M
2020-06-30	Reported	$153.10M*	$140.50M	$12.60M*	$362.00M	42.29%*	$18.20M*	$164.00M*	$25.90M	$89.70M	(m)	$26.80M
2020-03-31	Reported	$179.1M	(m)	(m)	(m)	50.27%	$13.00M	$214.60M	$23.40M	$73.20M	(m)	$33.90M
2019-12-31	Reported	$76M	(m)	(m)	(m)	24.43%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	$196.10M*	$183.40M	$12.70M*	$401.50M	48.84%*	$13.60M*	$185.40M*	$33.00M	$85.70M	(m)	$34.50M
2019-06-30	Reported	$231.80M*	$221.40M	$10.40M*	$373.60M	62.04%*	$20.30M*	$132.90M*	$26.70M	$85.90M	(m)	$45.30M
2019-03-31	Reported	-$645.6M	(m)	(m)	(m)	-178.05%	$25.10M	-$627.40M	$29.10M	$897.40M	(m)	-$156.00M
2018-12-31	Reported	$142M	(m)	(m)	(m)	37.23%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	$159.00M*	$149.60M	$9.40M*	$412.70M	38.53%*	$41.50M*	$237.50M*	$51.90M	$101.10M	(m)	$33.60M
2018-06-30	Reported	$225.50M*	$217.40M	$8.10M*	$444.50M	50.73%*	$53.50M*	$179.80M*	$61.70M	$82.30M	(m)	$45.00M
2018-03-31	Reported	$314.8M	(m)	(m)	(m)	80.88%	$37.60M	$275.70M	$53.20M	$35.70M	(m)	$64.50M
2017-12-31	Reported	$146.7M	(m)	(m)	(m)	31.57%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	$331.50M*	$323.80M	$7.70M*	$445.50M	74.41%*	$22.00M*	$258.50M*	$19.50M	(m)	$47.20M	$44.40M
2017-06-30	Reported	$96.20M*	$88.50M	$7.70M*	$444.60M	21.64%*	$20.90M*	$70.70M*	$18.90M	(m)	$67.40M	$100.20M
2017-03-31	Reported	$271.5M	(m)	(m)	(m)	73.28%	$15.60M	$230.80M	$14.30M	(m)	$56.40M	$85.00M
2016-12-31	Reported	$182M	(m)	(m)	(m)	44.50%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	$246.80M*	$238.60M	$8.20M*	(m)	(m)	$9.10M*	$228.70M*	(m)	$45.90M	$100.10M	$77.30M
2016-06-30	Reported	$293.10M*	$285.20M	$7.90M*	(m)	(m)	$10.40M*	(m)	(m)	(m)	$72.20M	$79.60M
2016-03-31	Reported	$371.4M	(m)	(m)	(m)	100.65%	$3.80M	(m)	(m)	(m)	$5.00M	$128.40M
2015-12-31	Reported	$162.9M	(m)	(m)	(m)	40.23%	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	$395.30M*	$387.00M	$8.30M*	(m)	(m)	$10.50M*	(m)	(m)	$9.60M	-$17.30M*	$272.40M
2015-06-30	Reported	$180.20M*	$171.80M	$8.40M*	(m)	(m)	$3.80M*	(m)	(m)	$49.41M	$110.00M	$69.20M
2015-03-31	Reported	-$6.5M	(m)	(m)	(m)	-1.98%	$4.00M	(m)	(m)	$110.21M	$211.30M	-$200.00K
2014-12-31	Reported	$187.46M	(m)	(m)	(m)	54.13%	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$24.13M*	-$32.24M	$8.11M*	(m)	(m)	$13.64M*	(m)	(m)	$118.88M	$202.51M	-$10.60M
2014-06-30	Reported	$183.96M*	$176.32M	$7.64M*	(m)	(m)	$12.84M*	(m)	(m)	$39.74M	$68.03M	$61.18M
2014-03-31	Reported	$223.71M	(m)	(m)	(m)	77.30%	$18.68M	(m)	(m)	$12.45M	$30.21M	$75.69M
2013-12-31	Reported	-$20.74M	(m)	(m)	(m)	-7.18%	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	$112.31M*	$104.65M	$7.66M*	(m)	(m)	$9.42M*	(m)	(m)	$72.75M	$94.11M	$38.49M
2013-06-30	Reported	$129.98M*	$122.30M	$7.68M*	(m)	(m)	$4.84M*	(m)	(m)	$54.62M	$71.36M	$38.66M
2013-03-31	Reported	$102.2M	(m)	(m)	(m)	41.69%	$4.24M	(m)	(m)	$50.43M	$71.36M	$28.51M
2012-12-31	Reported	$135.89M	(m)	(m)	(m)	55.74%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	$87.63M*	$80.72M	$6.92M*	(m)	(m)	$6.73M*	$93.45M*	(m)	$65.16M	$68.63M	$30.38M
2012-06-30	Reported	$111.88M*	$105.59M	$6.29M*	(m)	(m)	$43.64M*	$87.39M*	(m)	$37.10M	$53.26M	$30.97M
2012-03-31	Reported	$113.39M	(m)	(m)	(m)	55.52%	$40.28M	$37.59M	(m)	$33.66M	$39.79M	$33.18M
2011-12-31	Reported	$68.41M	(m)	(m)	(m)	35.05%	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	$107.97M*	$102.98M	$4.99M*	(m)	(m)	$17.84M*	$80.68M*	(m)	$59.43M	$16.66M	$17.64M
2011-06-30	Reported	$119.33M*	$114.49M	$4.84M*	(m)	(m)	$12.55M*	$64.54M*	(m)	$24.24M	$23.86M	$35.72M
2011-03-31	Reported	$42.61M	(m)	(m)	(m)	26.22%	$6.34M	$53.35M	(m)	$47.71M	$58.26M	$12.45M
2010-12-31	Reported	$19.07M	(m)	(m)	(m)	11.65%	(m)	(m)	(m)	(m)	(m)	(m)
2010-09-30	Reported	$67.52M*	$62.49M	$5.03M*	(m)	(m)	$4.08M*	$102.83M*	(m)	$40.34M	$45.59M	$18.22M
2010-06-30	Reported	$65.80M*	$61.22M	$4.58M*	(m)	(m)	$2.75M*	$35.23M*	(m)	$28.59M	$29.65M	$19.34M
2010-03-31	Reported	$36.82M	(m)	(m)	(m)	28.57%	$6.36M	$34.22M	(m)	$34.87M	$46.88M	$9.75M
2009-12-31	Reported	$2.3M	(m)	(m)	(m)	2.34%	(m)	(m)	(m)	(m)	(m)	(m)
2009-09-30	Reported	$14.24M*	$11.74M	$2.50M*	(m)	(m)	$24.06M*	$15.99M*	(m)	$31.55M	$41.17M	-$2.89M
2009-06-30	Reported	(m)	-$4.12M	(m)	(m)	(m)	(m)	(m)	(m)	$28.65M	$49.37M	-$3.20M

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$1.58B	(m)	(m)	(m)	49.58%	$520.50M	$1.56B	$384.40M	$550.00M	$755.80M	$379.20M
2024-12-31	Reported	$1.45B	(m)	(m)	(m)	50.38%	$246.50M	$1.33B	$309.70M	$481.00M	$709.70M	$343.90M
2023-12-31	Reported	$1.24B	(m)	(m)	(m)	53.19%	$230.40M	$978.00M	$257.50M	$408.00M	$477.10M	$289.50M
2022-12-31	Reported	$1.03B	(m)	(m)	(m)	53.25%	$138.80M	$802.50M	$151.60M	$322.90M	$482.10M	$223.30M
2021-12-31	Reported	$605.8M	(m)	(m)	(m)	35.94%	$120.80M	$598.20M	$122.50M	$540.10M	$467.00M	$118.10M
2020-12-31	Reported	$643.5M	(m)	(m)	(m)	43.38%	$59.30M	$755.70M	$108.10M	$357.70M	(m)	$124.10M
2019-12-31	Reported	-$141.7M	(m)	(m)	(m)	-9.78%	$83.70M	-$206.60M	$117.60M	$1.18B	(m)	-$60.50M
2018-12-31	Reported	$841.3M	(m)	(m)	(m)	51.68%	$184.40M	$778.40M	$198.70M	$357.90M	$265.80M	$169.70M
2017-12-31	Reported	$845.9M	(m)	(m)	(m)	49.03%	$86.30M	$474.20M	$105.70M	$264.60M	$330.10M	$351.60M
2016-12-31	Reported	$1.09B	(m)	(m)	(m)	68.38%	$38.00M	$643.60M	$72.70M	$147.60M	$316.80M	$346.50M
2015-12-31	Reported	$731.9M	(m)	(m)	(m)	49.93%	$49.80M	$382.80M	(m)	$245.10M	$452.70M	$392.80M
2014-12-31	Reported	$571M	(m)	(m)	(m)	44.32%	$47.40M	(m)	(m)	$242.50M	$381.30M	$185.10M
2013-12-31	Reported	$323.76M	(m)	(m)	(m)	28.99%	$31.91M	(m)	(m)	$299.35M	$394.01M	$104.34M
2012-12-31	Reported	$448.79M	(m)	(m)	(m)	48.99%	$111.91M	$323.63M	(m)	$173.39M	$201.75M	$136.23M
2011-12-31	Reported	$338.32M	(m)	(m)	(m)	45.52%	$35.98M	$250.19M	(m)	$180.01M	$156.48M	$81.87M
2010-12-31	Reported	$189.23M	(m)	(m)	(m)	31.92%	$18.64M	$211.53M	(m)	$165.31M	$188.61M	$43.95M
2009-12-31	Reported	$37.15M	(m)	(m)	(m)	10.35%	$95.40M	$99.72M	(m)	$120.37M	$171.89M	-$695.00K
2008-12-31	Reported	-$77.52M	(m)	(m)	(m)	-27.54%	$124.42M	-$40.43M	(m)	$239.18M	$94.31M	-$34.39M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Viatris Inc (VTRS)	United States	$20.008B	-0.00
Royalty Pharma plc (RPRX)	United States	$22.628B
Jazz Pharmaceuticals plc (JAZZ)		$15.333B	16.07
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
INSMED Inc (INSM)	United States	$26.566B	-26.60
Summit Therapeutics Inc. (SMMT)	United States	$13.071B	-13.21
BridgeBio Pharma, Inc. (BBIO)	United States	$12.947B	-20.72
CORCEPT THERAPEUTICS INC (CORT)	United States	$12.804B	169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)	United States	$11.879B	151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)	United States	$11.859B	-38.17